Ursodeoxycholic acid in primary biliary cirrhosis

Seminars in Liver Disease

Volumn 17, Issue 2, 1997, Pages 125-128

  Combes, Burton ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Placebo controlled therapeutic trials; Randomized

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIINFLAMMATORY AGENT; ASPARTATE AMINOTRANSFERASE; BILE ACID; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; URSODEOXYCHOLIC ACID;

ARTICLE; CHOLESTASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HEPATITIS; HUMAN; LIVER TRANSPLANTATION; MALE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

EID: 0030900380     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007190     Document Type: Article

References (13)

1. Poupon R, Chretien Y, Poupon RE, et al: Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1:834-6, 1987.
2. David R, Kurtz W, Strohm WD, Leuschner U. Die Wirkung von Ursodeoxycholsäure bei chronischen Leberkrankungen: Eine Pilotstudie. Z Gastroenterol 23:420, 1985.
3. Poupon RE, Balkau B, Eschwege E, Poupon R: The UDCA-PBC Study Group: A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 324:1548-54, 1991.
4. Heathcote EJ, Cauch-Dudek K, Walter V, et al: The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 19.1149-56, 1994.
5. Lindor DL, Dickson ER, Baldus WP, et al: Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 106:1284-90, 1994.
6. Combes B, Carithers RL Jr, Maddrey WC, et al: A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 22:759-66, 1995.
7. Kilmurry MR, Heathcote EJ, Kudek KC, et al: Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis? Hepatology 23:1148-53, 1996.
8. Lindor DL, Therneau TM, Jorgensen RA, et al: Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 110:1515-8, 1996.
9. Poupon RE, Poupon R, Balkau B, The UDCA-PBC Study Group: Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 330:1342-7, 1994.
10. Carithers RL, Luketic VA, Peters M, et al: Extended follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis [abstract]. Gastroenterology 110: A1163, 1996.
11. Heathcote EJ, Lindor KD, Poupon R. et al: Combined analysis of French, American and Canadian randomized controlled trials of ursodeoxycholic acid therapy in primary biliary cirrhosis [abstract]. Gastroenterology 108:A1082, 1995.
12. Heuman DM. Hepatoprotective properties of ursodeoxycholic acid. Gastroenterology 104:1865-70, 1993.
13. Calmus Y, Gane P, Rouger P, Poupon R: Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 11:12-5, 1990.